1 / 1
Inclisiran sodium API (Active Pharmaceutical Ingredient) is studied primarily in the field of RNA interference (RNAi) and cardiovascular therapeutics. As a double-stranded siRNA targeting the PCSK9 gene, it is used in preclinical and clinical research to evaluate long-acting gene-silencing strategies for lowering LDL-C (low-density lipoprotein cholesterol). It also serves as a model compound for investigating siRNA delivery systems, stability, and liver-targeted RNA therapeutics.
Inclisiran sodium API works by silencing the PCSK9 gene in hepatocytes, leading to decreased production of PCSK9 protein. This results in enhanced recycling of LDL receptors and greater clearance of LDL cholesterol from the blood. Its function as a long-acting cholesterol-lowering agent supports its use in treating hypercholesterolemia and reducing the risk of cardiovascular disease. As an API, it forms the core active component in Inclisiran-based drug formulations.
It is primarily studied in RNA interference (RNAi) and cardiovascular therapeutics to evaluate long-acting gene-silencing strategies aimed at lowering LDL-C.
It acts as a double-stranded siRNA that silences the PCSK9 gene in hepatocytes, reducing PCSK9 protein production and enhancing LDL receptor recycling.
By increasing the clearance of LDL cholesterol from the blood, it supports research into treating hypercholesterolemia and reducing cardiovascular disease risk.
It serves as a key model compound for investigating siRNA delivery systems, compound stability, and targeted RNA therapeutics in the liver.
It specifically targets the PCSK9 gene in liver cells (hepatocytes) to decrease PCSK9 protein production.
As an Active Pharmaceutical Ingredient (API), it acts as the core active therapeutic component in Inclisiran-based drug formulations.
